Next-Generation mRNA Design: Increasing mRNA potency with a New Cap Analog

mRNA vaccines and therapeutics are expanding rapidly, fueled in part by the extraordinary distribution and success of the COVID-19 vaccines. An essential part of the success of any mRNA therapeutic is the 5’ cap structure, which is critical to the stability and expression of an mRNA.

In this webinar, Dr. Chunping Xu, Director of Chemistry R&D for TriLink Biotechnologies, will discuss the latest progress in next-generation mRNA design. Attendees will learn about how major capping strategies differ in their manufacturing costs, time, complexity, and availability. In addition, Dr. Xu will show how TriLink is continuing to innovate in this technology as the company debuts a novel Cap1 structure.

A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelist.